SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1010 Name of the Signatory :- DEBASHIS DEYDesignation :- Company Secretary and Compliance Officer SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Clarification - Increase In Volume
With reference to your aforesaid letters, we confirm that the Company is in compliance with the requirements of Regulation 30 of the SEBI (LODR) Regulations, 2015 and that we are not aware of any information at this moment, which in our opinion may have a bearing on the price / volume behavior in our scrip. We remain committed to make adequate and timely disclosure of any material or price sensitive information to the Stock Exchanges in compliance with the applicable regulations. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Clarification sought from Sun Pharma Advanced Research Company Ltd
The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on January 1, 2021, with reference to Movement in Volume.The reply is awaited. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Closure of Trading Window
This is to inform you that, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and the Code of Conduct for Prevention of Insider Trading ('The CoC'), the Trading Window for trading by Designated Persons of the Company and their Immediate Relatives shall be closed with effect from Friday, 1st January 2021 till 48 hours after the declaration of financial results of the Company for the quarter ended 31st December 2020. The date of Board Meeting for declaration of the financial results for the quarter ended 31st December 2020 will be intimated in due course. This is for your information and record. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Company has issued duplicate share certificates as per attached details. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 09, 2020 for Raksha Sudhir Valia SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosure Of Related Party Transactions - September 2020
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended September 30, 2020. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 01, 2020 for Raksha Sudhir Valia SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of Board Meeting Held On 9Th November 2020.
The Board of Directors of the Company at their meeting held from 07:00 pm to 08:15 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 30th September 2020 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I. This is for your information and record. Thanking you, Yours faithfully, SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of Board Meeting Held On 9Th November 2020.
The Board of Directors of the Company at their meeting held from 07:00 pm to 08:15 pm today, inter alia, took on record and duly approved the Un-audited financial results of the Company for the quarter ended 30th September 2020 which is enclosed herewith along with the Limited Review Report of the Auditors thereon as Annexure I. This is for your information and record. Thanking you, Yours faithfully,